Changes in primary breast cancer heterogeneity may augment midtreatment MR imaging assessment of response to neoadjuvant chemotherapy

Radiology

Volumn 272, Issue 1, 2014, Pages 100-112

  Parikh, Jyoti ^a   Selmi, Mariyah ^b   Charles Edwards, Geoff ^b   Glendenning, Jennifer ^a   Ganeshan, Balaji ^c   Verma, Hema ^a   Mansi, Janine ^a   Harries, Mark ^a   Tutt, Andrew ^a   Goh, Vicky ^a,b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; ONCO TAIN; TAXCEUS; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; ENTROPY; FEMALE; HUMAN; IMAGE ANALYSIS; LOADING DRUG DOSE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGIC COMPLETE RESPONSE; PREDICTOR VARIABLE; PRIORITY JOURNAL; RANK SUM TEST; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; AGED; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CONTRAST MEDIA; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOADJUVANT THERAPY; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SOFTWARE; SUBTRACTION TECHNIQUE; TAXOIDS; TREATMENT OUTCOME;

EID: 84903695651     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.14130569     Document Type: Article

References (53)

1. Kaufmann M, von Minckwitz G, Mamounas EP, et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol 2012;19(5):1508-1516.
2. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nineyear results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001;(30):96-102.
3. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005;97(3):188-194. (Pubitemid 40277368)
4. Mieog JS, van der Hage JA, van de Velde CJ. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg 2007;94(10):1189-1200. (Pubitemid 47584766)
5. Esserman L, Hylton N, Yassa L, Barclay J, Frankel S, Sickles E. Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging. J Clin Oncol 1999;17(1):110-119. (Pubitemid 29022384)
6. Weatherall PT, Evans GF, Metzger GJ, Saborrian MH, Leitch AM. MRI vs. histologic measurement of breast cancer following chemotherapy: comparison with x-ray mammography and palpation. J Magn Reson Imaging 2001;13(6):868-875. (Pubitemid 32479944)
7. Schnall MD, Blume J, Bluemke DA, et al. MRI detection of distinct incidental cancer in women with primary breast cancer studied in IBMC 6883. J Surg Oncol 2005;92(1):32-38. (Pubitemid 41416426)
8. Van Goethem M, Schelfout K, Dijckmans L, et al. MR mammography in the pre-operative staging of breast cancer in patients with dense breast tissue: comparison with mammography and ultrasound. Eur Radiol 2004;14(5):809-816. (Pubitemid 38678900)
9. Berg WA, Gutierrez L, NessAiver MS, et al. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology 2004;233(3):830-849.
10. Herrada J, Iyer RB, Atkinson EN, Sneige N, Buzdar AU, Hortobagyi GN. Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma. Clin Cancer Res 1997;3(9):1565-1569. (Pubitemid 27431564)
11. Drew PJ, Kerin MJ, Mahapatra T, et al. Evaluation of response to neoadjuvant chemoradiotherapy for locally advanced breast cancer with dynamic contrast-enhanced MRI of the breast. Eur J Surg Oncol 2001;27(7):617-620. (Pubitemid 33062166)
12. Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Sudilovsky D, Hylton NM. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR Am J Roentgenol 2002;179(5):1193-1199. (Pubitemid 35204372)
13. Bodini M, Berruti A, Bottini A, et al. Magnetic resonance imaging in comparison to clinical palpation in assessing the response of breast cancer to epirubicin primary chemotherapy. Breast Cancer Res Treat 2004;85(3):211-218. (Pubitemid 38987254)
14. Rosen EL, Blackwell KL, Baker JA, et al. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. AJR Am J Roentgenol 2003;181(5):1275-1282. (Pubitemid 37296403)
15. Abraham DC, Jones RC, Jones SE, et al. Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer 1996;78(1):91-100. (Pubitemid 26189909)
16. Londero V, Bazzocchi M, Del Frate C, et al. Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol 2004;14(8):1371-1379. (Pubitemid 39162217)
17. Yeh E, Slanetz P, Kopans DB, et al. Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. AJR Am J Roentgenol 2005;184(3):868-877. (Pubitemid 43899515)
18. Balu-Maestro C, Chapellier C, Bleuse A, Chanalet I, Chauvel C, Largillier R. Imaging in evaluation of response to neoadjuvant breast cancer treatment benefits of MRI. Breast Cancer Res Treat 2002;72(2):145-152. (Pubitemid 34407209)
19. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11(16):5678-5685. (Pubitemid 41170290)
20. Caudle AS, Gonzalez-Angulo AM, Hunt KK, et al. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010;28(11):1821-1828.
21. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007;608:1-22.
22. Wasser K, Sinn HP, Fink C, et al. Accuracy of tumor size measurement in breast cancer using MRI is influenced by histological regression induced by neoadjuvant chemotherapy. Eur Radiol 2003;13(6):1213-1223. (Pubitemid 36790621)
23. Denis F, Desbiez-Bourcier AV, Chapiron C, Arbion F, Body G, Brunereau L. Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer. Eur J Surg Oncol 2004;30(10):1069-1076. (Pubitemid 40267811)
24. Rieber A, Zeitler H, Rosenthal H, et al. MRI of breast cancer: influence of chemotherapy on sensitivity. Br J Radiol 1997;70(833):452-458. (Pubitemid 27229264)
25. Davnall F, Yip CS, Ljungqvist G, et al. Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice? Insights Imaging 2012;3(6):573-589.
26. Ahmed A, Gibbs P, Pickles M, Turnbull L. Texture analysis in assessment and prediction of chemotherapy response in breast cancer. J Magn Reson Imaging 2013;38(1):89-101.
27. Harrison LC, Luukkaala T, Pertovaara H, et al. Non-Hodgkin lymphoma response evaluation with MRI texture classification. J Exp Clin Cancer Res 2009;28:87.
28. Alic L, van Vliet M, van Dijke CF, Eggermont AM, Veenland JF, Niessen WJ. Heterogeneity in DCE-MRI parametric maps: a biomarker for treatment response? Phys Med Biol 2011;56(6):1601-1616.
29. O'Connor JP, Rose CJ, Jackson A, et al. DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6. Br J Cancer 2011;105(1):139-145.
30. Miller P, Astley S. Classification of breast tissue by texture analysis. Image Vis Comput 1992;10(5):277-282.
31. Chan HP, Wei D, Helvie MA, et al. Computer-aided classification of mammographic masses and normal tissue: linear discriminant analysis in texture feature space. Phys Med Biol 1995;40(5):857-876.
32. Gupta R, Undrill PE. The use of texture analysis to delineate suspicious masses in mammography. Phys Med Biol 1995;40(5):835-855.
33. Garra BS, Krasner BH, Horii SC, Ascher S, Mun SK, Zeman RK. Improving the distinction between benign and malignant breast lesions: the value of sonographic texture analysis. Ultrason Imaging 1993;15(4):267-285. (Pubitemid 24090199)
34. Ganeshan B, Strukowska O, Skogen K, Young R, Chatwin C, Miles K. Heterogeneity of focal breast lesions and surrounding tissue assessed by mammographic texture analysis: preliminary evidence of an association with tumor invasion and estrogen receptor status. Front Oncol 2011;1:33.
35. James D, Clymer BD, Schmalbrock P. Texture detection of simulated microcalcification susceptibility effects in magnetic resonance imaging of breasts. J Magn Reson Imaging 2001;13(6):876-881. (Pubitemid 32479945)
36. Sinha S, Lucas-Quesada FA, DeBruhl ND, et al. Multifeature analysis of Gd-enhanced MR images of breast lesions. J Magn Reson Imaging 1997;7(6):1016-1026. (Pubitemid 28372876)
37. Gibbs P, Turnbull LW. Textural analysis of contrast-enhanced MR images of the breast. Magn Reson Med 2003;50(1):92-98. (Pubitemid 36841864)
38. Chen W, Giger ML, Li H, Bick U, Newstead GM. Volumetric texture analysis of breast lesions on contrast-enhanced magnetic resonance images. Magn Reson Med 2007;58(3):562-571. (Pubitemid 350154967)
39. Woods BJ, Clymer BD, Kurc T, et al. Malignant-lesion segmentation using 4D co-occurrence texture analysis applied to dynamic contrast-enhanced magnetic resonance breast image data. J Magn Reson Imaging 2007;25(3):495-501. (Pubitemid 46355410)
40. Holli K, Lääperi AL, Harrison L, et al. Characterization of breast cancer types by texture analysis of magnetic resonance images. Acad Radiol 2010;17(2):135-141.
41. Di Giovanni P, Ahearn TS, Semple SI, et al. The biological correlates of macroscopic breast tumour structure measured using fractal analysis in patients undergoing neoadjuvant chemotherapy. Breast Cancer Res Treat 2012;133(3):1199-1206.
42. Rose CJ, Mills SJ, O'Connor JPB, et al. Quantifying spatial heterogeneity in dynamic contrast-enhanced MRI parameter maps. Magn Reson Med 2009;62(2):488-499.
43. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007;25(28):4414-4422. (Pubitemid 350013847)
44. Ganeshan B, Miles KA, Young RC, Chatwin CR. Hepatic entropy and uniformity: additional parameters that can potentially increase the effectiveness of contrast enhancement during abdominal CT. Clin Radiol 2007;62(8):761-768. (Pubitemid 46971655)
45. Chen JH, Feig B, Agrawal G, et al. MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. Cancer 2008;112(1):17-26.
46. Bahri S, Chen JH, Mehta RS, et al. Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab. Ann Surg Oncol 2009;16(6):1619-1628.
47. Hylton NM, Blume JD, Bernreuter WK, et al. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy - results from ACRIN 6657/I-SPY TRIAL. Radiology 2012;263(3):663-672.
48. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and longterm survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26(8):1275-1281.
49. Rasbridge SA, Gillett CE, Seymour AM, et al. The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Br J Cancer 1994;70(2):335-341. (Pubitemid 24247160)
50. Semple SI, Gilbert FJ, Redpath TW, et al. Correlation of MRI/PET rim enhancement in breast cancer: a delivery related phenomenon with therapy implications? Lancet Oncol 2003;4(12):759. (Pubitemid 37527211)
51. Ganeshan B, Miles KA, Young RC, Chatwin CR. Texture analysis in non-contrast enhanced CT: impact of malignancy on texture in apparently disease-free areas of the liver. Eur J Radiol 2009;70(1):101-110.
52. Yuan Y, Chen XS, Liu SY, Shen KW. Accuracy of MRI in prediction of pathologic complete remission in breast cancer after preoperative therapy: a meta-analysis. AJR Am J Roentgenol 2010;195(1):260-268.
53. Nahleh Z, Sivasubramaniam D, Dhaliwal S, Sundarajan V, Komrokji R. Residual cancer burden in locally advanced breast cancer: a superior tool. Curr Oncol 2008;15(6):271-278.